Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study by Hegade VS et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, 
Storey J, Dukes GE, Corrigan M, Oude-Elferink RP, Beuers U,  
Hirschfield GM, Jones DEJ.  
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in 
primary biliary cholangitis: a double-blind, randomised, placebo-controlled, 
crossover, phase 2a study.  
The Lancet 2017 
DOI: https://doi.org/10.1016/S0140-6736(17)30319-7  
 
Copyright: 
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
DOI link to article: 
https://doi.org/10.1016/S0140-6736(17)30319-7  
Date deposited:   
03/03/2017 
Embargo release date: 
08 August 2017  
1 
 
Effect of ileal bile acid transporter inhibitor GSK2330672 on 
pruritus in primary biliary cholangitis: a double-blind, 
randomised, placebo-controlled, crossover, phase 2a study 
 
Authors: 
Vinod S Hegade*1, Stuart FW Kendrick*2, Robert L Dobbins3, Sam R Miller2, Douglas 
Thompson2, Duncan Richards2, James Storey2, George E Dukes3, Margaret Corrigan4, Ronald 
PJ Oude Elferink5, Ulrich Beuers5, Gideon M Hirschfield4, David E Jones1 
Affiliations  
1NIHR Newcastle Biomedical Research Centre and Institute of Cellular Medicine, Framlington 
Place, Newcastle University, Newcastle upon Tyne, United Kingdom 
2GlaxoSmithKline, Stevenage, United Kingdom. 
3GlaxoSmithKline, Research Triangle Park, NC, United States 
4University of Birmingham and NIHR Birmingham Liver Biomedical Research Unit, 
Birmingham, United Kingdom 
5Tytgat Institute for Liver and Intestinal Research, Department of Gastroenterology and 
Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The 
Netherlands 
* These authors contributed equally to the manuscript 
2 
 
Corresponding Author 
 
Dr Vinod S Hegade 
NIHR Newcastle Biomedical Research Centre 
Institute of Cellular Medicine 
Faculty of Medical Sciences  
Newcastle University  
Newcastle upon Tyne NE2 4HH  
United Kingdom 
Phone: +441912088782 E-mail: Vinod.hegade@ncl.ac.uk  
  
3 
 
Summary 
Background: Up to 70% of patients with primary biliary cholangitis develop pruritus (itch) 
during the course of their disease. Treatment of pruritus in primary biliary cholangitis is 
challenging and novel therapies are needed. Ursodeoxycholic acid, the standard first-line 
treatment for primary biliary cholangitis, is largely ineffective for pruritus. We investigated the 
efficacy and safety of GSK2330672, a selective inhibitor of human ileal bile acid transporter 
(IBAT), in patients with primary biliary cholangitis with pruritus.  
Methods: We conducted this phase 2a, double-blind, randomised, placebo-controlled, 
crossover trial in two UK medical centres. Following 2 weeks of open placebo run-in, patients 
were randomly assigned in a 1:1 ratio with a block size of 4 to receive GSK2330672 or placebo 
twice daily during two consecutive 14-day treatment periods in a crossover sequence. The 
treatment periods were followed by a 14-day single-blinded placebo follow-up period. The 
primary endpoints were safety of GSK2330672, assessed using clinical and laboratory 
parameters, and tolerability as rated by the Gastrointestinal Symptom Rating Scale. The 
secondary endpoints were changes in pruritus scores measured using the 0 to 10 numerical 
rating scale (NRS), primary biliary cholangitis-40 (PBC-40) itch domain score and 5-D itch 
scale, changes in serum total bile acids and 7 alpha hydroxy-4-cholesten-3-one (C4), and 
changes in the pharmacokinetic parameters of ursodeoxycholic acid and its conjugates. The 
trial was registered with ClinicalTrials.gov, number NCT01899703. 
Findings: Between March 10, 2014, and Oct 7, 2015, we enrolled 22 patients. 11 patients were 
assigned to receive intervention followed by placebo (sequence 1), and 11 patients were 
assigned to receive placebo followed by intervention (sequence 2). One patient assigned to 
sequence 2 withdrew consent prior to receiving randomised therapy. One patient did not attend 
the placebo follow-up period, but was included in the final analysis. GSK2330672 treatment 
for 14 days was safe with no serious adverse events reported. Diarrhoea was the most frequent 
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adverse event during treatment with GSK2330672 (seven with GSK2330672 vs one with 
placebo) and headache was the most frequent adverse event during treatment with placebo 
(seven with placebo vs six with GSK2330672). After GSK2330672 treatment, the percentage 
changes from baseline itch scores were –57% (95% CI –73 to –42, p<0·0001) in the NRS, –
31% (–42 to –20, p<0·0001) in the PBC-40 itch domain and –35% (–45 to –25, p<0·0001) in 
the 5-D itch scale. GSK2330672 produced significantly greater reduction from baseline than 
the double-blind placebo in the NRS (–23%, 95% CI –45 to –1; p=0·037), PBC-40 itch domain, 
(–14%, –26 to –1; p=0·034), and 5-D itch scale (–20%, –34 to –7; p=0·0045). After 
GSK2330672 treatment, serum total bile acid concentrations declined by 50% (95% CI –37 to 
–61, p<0·0001) from 30 to 15 μM, with a significant 3·1-times increase (95% CI 2·4 to 4·0, 
p<0·0001) in serum C4 concentrations from 7·9 to 24·7ng/mL. 
Interpretation: In patients with primary biliary cholangitis with pruritus, 14 days of ileal bile 
acid transporter inhibition by GSK2330672 was generally well tolerated without serious 
adverse events, and demonstrated efficacy in reducing pruritus severity. GSK2330672 has the 
potential to be a significant and novel advance for the treatment of pruritus in primary biliary 
cholangitis. Diarrhoea, the most common adverse event associated with GSK2330672 
treatment, might limit the long-term use of this drug. 
Funding: GlaxoSmithKline and National Institute for Health Research. 
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Research in context 
Evidence before this study: 
Chronic pruritus is a common symptom associated with cholestatic liver diseases and, along 
with fatigue, accounts for the greatest burden of symptoms in patients with primary biliary 
cholangitis. Up to 70% of patients develop pruritus at some point during the course of their 
disease and many patients describe persistent or severe pruritus which can be debilitating. This 
form of pruritus goes beyond cutaneous irritation, with secondary effects through sleep 
deprivation, daytime somnolence, fatigue, depression, and even on occasions, suicidal ideation. 
Overall, patients with primary biliary cholangitis and pruritus have a poor quality of life 
reflecting the limitations of current approaches to treatment. We searched PubMed for clinical 
studies published in English between Jan 1, 1950, and Sept 1, 2016, with terms “PBC”, 
“cholestasis”, “pruritus”, or “itch” and “bile acids”, “bile salts”, “IBAT”, or “ASBT”. 
Ursodeoxycholic acid, the standard of care for primary biliary cholangitis, has no substantial 
effect on pruritus and obeticholic acid, a second-line therapy, can actually worsen it. The four 
classes of available, guideline recommended drugs for pruritus include bile acid sequestrants 
(cholestyramine), pregnane X receptor agonists (rifampicin), opioid antagonists (naltrexone), 
and selective serotonin reuptake inhibitors (sertraline). However, the strength of evidence for 
these drugs is poor to moderate with only rifampicin and naltrexone ever studied in 
methodologically robust randomised controlled trials. Furthermore, rifampicin is associated 
with a risk of liver injury necessitating regular monitoring of liver enzymes, and naltrexone is 
associated with unpleasant symptoms of the opioid withdrawal syndrome. Cholestyramine 
remains the only licensed treatment but is poorly tolerated by many patients due to its 
unpleasant taste and texture, resulting in poor therapy adherence. Another bile acid sequestrant 
colesevelam has better tolerability but the only randomised controlled trial so far did not show 
that it was more effective than placebo in treating pruritus in primary biliary cholangitis. 
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Added value of this study 
This study is a first-in-class, randomised, placebo-controlled trial of an ileal bile acid 
transporter (IBAT) inhibitor to treat pruritus in patients with primary biliary cholangitis. Using 
three different complementary patient-reported outcome measurements, GSK2330672 showed 
greater effects than placebo in reducing itch intensity, as well as night-time sleep interference 
and daytime fatigue. GSK2330672 significantly decreased serum activity of autotaxin, which 
forms lysophosphatidic acid, a novel proposed pruritogen in cholestasis shedding further light 
on the potential mechanisms for cholestatic pruritus and the actions of the drug. In addition to 
improving symptoms of primary biliary cholangitis, this study has shown that pharmacological 
inhibition of IBAT can be used as a therapeutic strategy to decrease the circulating bile acid 
pool in cholestatic patients. GSK2330672 decreased serum conjugated bile acids and resulted 
in ~50% decrease in total bile acid concentrations. 
Implication of all the available evidence 
Because of the great burden of pruritus in patients and the limitations of treatment options, 
there is a real unmet need for effective anti-pruritic therapies in primary biliary cholangitis. 
IBAT inhibitors are a novel class of drugs that have shown therapeutic potential in cholestasis. 
The results of our early phase randomised controlled trial in conjunction with previous 
experimental evidence and healthy volunteer trials provide support to further investigate anti-
pruritic effect of IBAT inhibitor drugs in larger and longer-term studies of patients with 
primary biliary cholangitis. 
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Introduction 
Primary Biliary Cholangitis (previously cirrhosis, PBC) 1 is a chronic autoimmune liver disease 
characterised by progressive cholestasis. Pruritus (itch) is a frequent and troublesome symptom 
in PBC patients. The natural history of PBC suggests that 60-70% of patients develop pruritus 
at some point during the disease process.2-4 The pathogenesis of cholestatic pruritus is complex 
and a number of putative pruritogens have been proposed.5 The use of ursodeoxycholic acid 
(UDCA), the current standard of care in PBC, has improved outcomes in PBC but has not been 
shown to improve pruritus.6  
The bile acid sequestrant cholestyramine is often given to treat pruritus, but its effectiveness in 
practice is limited. Despite its modest evidence base, and poor tolerability profile, it is the only 
US Food and drug Administration (FDA)-approved therapy for cholestatic pruritus and is 
recommended by both the American and European practice guidelines as the first-line agent.7, 
8 Colesevelam is a better tolerated bile acid sequestrant, but was not efficacious in the only 
randomised controlled trial reported so far.9 Other drug therapies (rifampicin, naltrexone, and 
sertraline), although recommended by the scientific guidelines,7,8 are not actually licensed for 
treating cholestatic pruritus. Moreover, they have the disadvantage of needing regular 
monitoring due to risk of liver injury and other limiting adverse effects. This is particularly an 
issue with rifampicin, the most widely used second-line therapy, which has well reported 
hepatotoxicity.10 In clinical practice, response rates less than 50% are common for most of the 
guideline recommended drugs11 and despite their step-wise use, many patients report refractory 
itch, which can only be treated by invasive (usually temporary) treatments such as nasobiliary 
drainage12 or liver transplantation (the only definitive cure). Therefore, effective anti-pruritic 
drug therapy is an unmet clinical need in primary biliary cholangitis and other cholestatic liver 
diseases.13 
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The paucity of effective anti-pruritic therapies in primary biliary cholangitis is probably 
compounded by the fact that the key emerging second-line disease modifying agent, obeticholic 
acid, which has been licensed by the FDA and European Medicines Agency, is associated with 
an increased frequency and severity of pruritus.14, 15 Many other bile acid-based therapies in 
primary biliary cholangitis that are in development16 might also be associated with pruritus. 
Therefore, effective pruritus management in primary biliary cholangitis is likely to become 
increasingly important and challenging and new approaches are needed. 
Ileal bile acid transporter (IBAT, also called apical sodium-dependent bile acid transporter 
[ASBT]) is an integral brush border membrane glycoprotein mainly expressed in the distal 
ileum.17, 18 The main physiological function of IBAT is reabsorption of bile acids and 
maintenance of their enterohepatic circulation. In cholestatic liver disease, ileal bile acid 
absorption is increased19, 20 and inhibiting ileal bile acid transport was proposed to prevent 
inappropriate conservation of bile acids.21 Using an IBAT inhibitor to reduce bile acid 
reabsorption and modulate the bile acid pool in the systemic circulation is an unexplored 
therapeutic strategy in primary biliary cholangitis, a condition in which retention of toxic 
hydrophobic bile acids is postulated to play a key pathogenetic role. 
To date, published reports of IBAT inhibitor drugs include a study in healthy people 
(A4250),22 two reports in animal models of cholestasis (A4250 and SC435)23,24 and a report 
of lopixibat chloride (formerly LUM001) in patients with primary biliary cholangitis and 
pruritus.25 GSK2330672 is a highly potent, soluble, minimally absorbed, selective inhibitor of 
the human IBAT. It has been assessed in animal models of type 2 diabetes mellitus (T2DM) 
and an early phase trial of T2DM patients.26,27 In two phase 1 studies (59 healthy volunteers) 
it was well tolerated with a good safety profile at a dose range of 0・1 to 90 mg (unpublished 
data from clinical trial NCT01416324 and NCT01607385). 
9 
 
Here we report the first randomised, placebo controlled, double-blind, crossover, phase 2 trial 
of an IBAT inhibitor in people with primary biliary cholangitis and pruritus. We postulated 
that GSK2330672 would interrupt enterohepatic circulation of bile acids and exert therapeutic 
benefit on pruritus associated with primary biliary cholangitis. 
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Methods 
Study design and patients 
BAT117213 was a phase 2a randomised, double-blind, placebo-controlled study to assess the 
safety, tolerability, pharmacokinetics, and pharmacodynamics of repeat doses of GSK2330672 
in patients with primary biliary cholangitis and symptoms of pruritus (figure 1). This study was 
done at two centres in the UK: Newcastle Upon Tyne Hospitals NHS Foundation Trust, 
Newcastle upon Tyne, and University Hospitals Birmingham NHS Foundation Trust, 
Birmingham, in collaboration with the UK-PBC Consortium.28 The National Research Ethics 
Service Committee North East and Sunderland (REC reference 13/NE/0290) and the Medicine 
and Healthcare products Regulatory Agency approved all versions of the study protocol which 
is available online.28 All recruitment sites obtained approval from their respective hospital 
Research and Development (R&D) departments before screening patients. All participants 
provided written informed consent before enrolment. The trial was done in accordance with 
the International Conference on Harmonisation Good Clinical Practice guidelines and the 
Declaration of Helsinki.29 The trial protocol is available online.28 
Patients were eligible for inclusion in the trial if they were aged 18–75 years, had proven or 
likely primary biliary cholangitis with ongoing pruritus, were on stable doses of UDCA for 
more than 8 weeks at the time of screening, and had serum alkaline phosphatase value no more 
than 10 times the upper limit of normal. Exclusion criteria are shown in the appendix. 
Eligible volunteers entered a 2 week open placebo run-in period followed by randomised, 
blinded, two-period crossover treatment periods (sequence 1 and sequence 2) of 14 days each 
during which patients received either GSK2330672 or placebo twice daily. Sequence 1 was 
GSK2330672 followed by placebo and sequence 2 was placebo followed by GSK2330672. 
There was no washout period between two treatment periods. Patients then entered 14 days of 
follow-up during which they received blinded placebo treatment. When taking GSK2330672 
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(or matching placebo), participants received 45 mg twice per day on days 1–3, and were then 
asked to increase the dose to 90 mg twice daily on days 4–14. 
Outcomes 
The primary objective of the study was to investigate the safety and tolerability of oral 
GSK2330672 when administered for 14 days to patients with primary biliary cholangitis with 
pruritus. The secondary objectives were to investigate the effects of oral GSK2330672 on 
participants’ experience of pruritus, study the effect of the drug on serum total bile acids and 
7 alpha hydroxy-4- cholesten-3-one (C4), a serum marker of bile acid synthesis, and investigate 
the steady-state pharmacokinetic parameters of UDCA and its taurine and glycine conjugates. 
Exploratory endpoints included changes in the concentrations of serum liver biochemistry, bile 
acid species, autotaxin (ATX) activity, and fibroblast growth factor (FGF19; appendix). 
Randomisation and masking 
A single randomisation schedule for all sites was generated using a dedicated randomisation 
creation and publishing tool for GlaxoSmithKline (GSK) studies (RandAll) by the GSK 
statistician. Randomisation numbers were allocated in a 1:1 ratio to sequence 1 or sequence 2 
with a block size of four. Randomisation numbers were allocated to participants by site staff 
.Patients, investigators, clinical trial site staff, and sponsor staff directly involved with the study 
were masked to treatment sequence assignment throughout the study. 
Statistical analysis 
The study was designed to estimate the effect of GSK2330672 (when co-administered with 
UDCA) relative to placebo on pruritus and the pharmacokinetics of UDCA. Due to the early 
clinical and exploratory nature of the study, no formal hypothesis testing was planned and the 
sample size was based on feasibility with consideration of efficacy (using pruritus 0–10 
numerical rating scale [NRS]) and potential pharmacokinetics interaction between 
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GSK2330672 and UDCA. An initial sample size of 40 participants was estimated to be 
sufficient for both efficacy and pharmacokinetics based on the assumption that GSK2330672 
was at least as efficacious as rifampicin and the SD was similar to that reported in trials of other 
anti-pruritic drugs.30, 31 Given the uncertainties associated with sample size assumptions, two 
interim analyses were done to assess futility and determine if sample size re-estimation was 
necessary. Data from the pruritus 0–10 NRS were reviewed by a non-blinded Interim Review 
Committee (composed of people not directly involved in study conduct). The first interim 
analysis was done after 11 patients had completed the treatment period, and a second interim 
analysis was done after 19 patients had completed the treatment period, at which point the final 
target sample size was reduced (appendix). The study was closed for recruitment after 22 
people were randomly assigned. 
To summarise the daily pruritus 0–10 point NRS during the placebo run-in period and each 
treatment period for each individual patient, we calculated trimmed means of weekly itch 
scores. Trimmed means removed the highest and lowest daily score (an average of the morning 
and evening scores) to provide more robust summary not influenced by potential outlying 
values. For statistical analysis we used the second week of each period to provide an analytical 
washout (i.e., 7 days between the analysed periods to allow treatment effects to stabilise). The 
efficacy endpoint analysis used a mixed effects model with fixed effect terms for treatment 
period and sequence, with participants treated as a random effect in the model. Baseline 
(placebo run-in) results were included in the model as an additional period. Point estimates and 
their associated 95% CI and p value were constructed for the mean differences of interest in 
pruritus scores (i.e., changes from baseline on each treatment and between double-blind 
GSK2330672 and placebo). The statistical analysis of pruritus scores in PBC-40 and 5-D itch 
was similarly done (appendix). Data on pharmacokinetics parameters, bile acids, and 
biomarkers were log transformed for analysis, and results are reported as percentage changes 
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or ratios. Although not formally a hypothesis-testing study, two-sided p values less than 0・05 
were considered statistically significant. All analyses were done using SAS, version 9.2 or 
greater (SAS Institute, Cary, NC, USA). This trial is registered on ClinicalTrials.gov, number 
NCT01899703. 
Role of the funding source 
The sponsor and main study funder (GlaxoSmithKline; GSK) was involved in the study design, 
data analysis, and data interpretation with inputs from VSH, DEJ, and GMH. The NIHR 
Newcastle Biomedical Research Centre provided additional funding but had no role in study 
design, data collection, analysis, or interpretation. The trial was supervised by the research and 
development department of the Newcastle Upon Tyne Hospitals NHS Foundation Trust and 
data collection occurred at the clinical trial units of the study centres. The corresponding author 
(VSH) had access to the raw data, did analysis of primary and secondary outcomes with SRM 
and DT (GSK statisticians) and wrote the study report. All authors had access to the data, 
reviewed the manuscript, and share final responsibility for the decision to submit for 
publication. 
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Results 
Between March 10, 2014, and Oct 7, 2015, we enrolled and randomised 22 patients. 21 patients 
completed all the planned study procedures as per protocol. One patient was withdrawn from 
the study due to withdrawal of consent in the placebo run-in period (figure 2). The safety 
population therefore comprised a total of the 22 randomly assigned patients, while the analysis 
population comprised 21 patients who completed all the planned study procedures as per 
protocol (although one patient did not attend the full follow-up period). 19 of 21 patients were 
taking UDCA during the study period at the guideline recommended dose. The baseline 
demographic and clinical characteristics of the participants are shown in table 1. A summary 
of the frequency of use of anti-pruritic treatments prior to the start of the study is provided in 
the appendix (p 15). As per the study protocol, use of these drugs was stopped at the study 
entry. 
All patients in the active treatment period started with GSK2330672 at a dose of 45 mg twice 
per day for 3 days and successfully increased to 90 mg twice per day on days 4–14. During the 
study there were no reports of serious adverse events. There were no clinically significant 
changes in vital signs, laboratory values or ECG parameters, and no positive faecal occult blood 
tests were reported. There were no reports of liver toxicity and no significant changes were 
seen in serum total bilirubin, alkaline phosphatase, or other liver enzymes during the study 
period (appendix p 16). 
Overall, GSK2330672 was well tolerated. A summary of all adverse events reported for more 
than one participant during any treatment period (irrespective of sequence) is given in table 2. 
The frequency of any adverse events was similar in active drug and placebo treatment periods 
(81% vs 81%). The most common adverse event observed during the study was headache, 
reported by 14 of 22 participants. 16 patients reported adverse events related to the 
gastrointestinal system. The most common GSK2330672-related adverse event was diarrhoea, 
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reported by seven participants, with five rating the severity as mild (lasting up to 4 days with 
no or minimal effect on daily life). The frequency of diarrhoea reported during GSK2330672 
treatment was significantly higher compared with placebo (seven patients during GSK2330672 
treatment vs one patient during placebo treatment, p=0・0391, post-hoc mid-p McNemar test). 
No patient discontinued the drug or had their dose decreased secondary to diarrhoea. Two 
adverse events (diarrhoea, abdominal distension) reported during GSK2330672 treatment and 
one adverse event of upper abdominal pain reported during placebo treatment were considered 
to be severe. 
After GSK2330672 treatment, changes from baseline itch scores were: -57% (95% CI -73 to -
42, p<0・0001) for NRS, -30% (-42 to -20, p<0・0001) for PBC-40 itch domain, and -35% (-
45 to -25, p<0・0001) for 5-D itch scale (figure 3). GSK2330672 reduced itch intensity 
significantly more than the double-blind placebo in all three scales: -23% (-1 to -45, p=0・
0374) for NRS, -14% (-1 to -26, p=0・0335) for PBC-40 itch domain, and -20% (-7 to -34, 
p=0・0045) for 5-D itch.  
For individual patients, changes in the weekly trimmed mean of their itch intensity score are 
shown in the appendix. Overall, the mean NRS itch intensity score decreased significantly from 
baseline after  GSK2330672 treatment period (appendix p 17) and the reduction was significant 
in both the sequences of treatment (appendix p 18). In the NRS, itch was also assessed for worst 
itch, bothersome itch, and sleep interference. Significant reductions were seen in these scores 
following GSK2330672 (appendix p 19). 
GSK2330672 treatment was also associated with significant reductions in the mean PBC-40 
itch domain and 5-D itch score (appendix p 20). The mean decrease from baseline in 5-D itch 
score after GSK2330672 treatment was significant in both sequences of treatment, whereas the 
decrease in PBC-40 itch domain score was only significant in sequence 2. Adjusting for 
16 
 
sequence and period, the mean PBC-40 itch domain and 5-D itch scores following 
GSK2330672 treatment were significantly lower than placebo. 
Analysis of other domains of PBC-40 showed a significantly greater reduction in the fatigue 
domain score after GSK2330672 treatment compared with placebo (–9%, 95% CI –3 to –16; 
p=0・0033). No significant changes were apparent for other domains of PBC-40 (appendix pp 
21–22). All five domains of the 5-D itch scale, including the disability domain, showed 
significantly lower scores after GSK2330672 compared with placebo (appendix pp 23–24). 
Serum total bile acid concentrations changed from baseline with a 50% decrease (95% CI –37 
to –61, p<0・0001) after GSK2330672 treatment compared with a 12% increase (–12 to 42, 
p=0・3540) after placebo. The changes in serum total bile acid concentrations following 
GSK2330672 were significant when compared with baseline and placebo (figure 4A) and the 
changes were reversed within 2 weeks of stopping GSK2330672. Conversely, faecal total bile 
acid showed a mean 36% increase after GSK2330672 (95% CI –1 to 85) compared with 16% 
decrease after placebo (–40 to 15). 
Serum concentrations of conjugated bile acids decreased after GSK2330672 compared with 
baseline (appendix p 25), with the largest percentage reductions observed in taurocholate (–
74%; 95% CI –53 to –86, p<0・0001), glycocholate (–64%; –23 to –83, p=0・0099), and 
taurochenodeoxycholate (–58%; –32 to –74, p=0・0007). In contrast, unconjugated primary 
bile acids cholate (–13%; –60 to 86, p=0・7040) and chenodeoxycholate (–4%; –34 to 38, p=0
・8049) did not change significantly after GSK2330672 (appendix p 25). A significant increase 
in serum UDCA (57%; 15 to 116, p=0・0062) and a marginal increase in serum deoxycholate 
(11%; –1 to 23%, p=0・0619) were observed after GSK2330672 (appendix p 25). No 
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significant changes from baseline were seen in any bile acid species after placebo treatment 
(appendix pp 27–29).  
There was a significant 3・1-times increase in serum C4 concentration from baseline after 
GSK2330672 treatment (95% CI 2・4 to 4・0, p<0・0001; figure 4B) and the increase was 
seen in both sequences of treatment. No significant changes in C4 were seen after placebo 
treatment. Significant decreases compared with baseline were seen in serum ATX activity (– 
11%, 95% CI –3 to –19; p=0·0070) and FGF19 concentration (–78%, –60 to –88; p<0·0001) 
following GSK2330672 treatment, but not after placebo (appendix). 
GSK2330672 is designed as a minimally absorbable agent with minimal systemic exposure. 
Eight of 22 participants had measurable plasma concentrations of GSK2330672 and the peak 
concentration (5・33 ng/mL, achieved at 2 h post-dose in one patient) is consistent with 
minimal systemic exposure.  All 14 patients who provided faecal samples for drug analysis had 
detectable GSK2330672 in the faeces. No GSK2330672-related metabolites were detected in 
plasma or urine. Comparing co-administration of UDCA with GSK2330672 or with placebo 
showed 90% CIs for UDCA maximum concentration (Cmax) and area under curve (AUC) 
ratios within conventional bioequivalence limits of 0・8–1・25 but reduced exposure in the 
metabolites tauroursodeoxycholic acid (TUDCA) and glyco ursodeoxycholic acid (GUDCA; 
appendix). 
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Discussion 
This trial of GSK2330672 shows safety and efficacy of a first-in-class, novel agent in treating 
pruritus associated with primary biliary cholangitis. Despite the substantial symptom burden 
and need for better anti-pruritic drugs, little progress in developing new treatments for pruritus 
in primary biliary cholangitis has been made. We have attempted to fill this treatment gap with 
the first randomised, placebo-controlled, crossover trial of an IBAT inhibitor drug in patients 
with primary biliary cholangitis and clinically significant pruritus. Our results suggest that 
interrupting enterohepatic circulation of bile acids by inhibiting IBAT with GSK2330672 
improves pruritus in patients with primary biliary cholangitis. 
We found that GSK2330672 at 45–90 mg dose, given twice per day for 2 weeks in patients 
with primary biliary cholangitis, was safe and generally well tolerated. No serious adverse 
events and no clinically significant abnormality related to haematology, clinical chemistry, or 
ECG was reported following GSK2330672 treatment. Diarrhoea was the most frequent adverse 
event associated with GSK2330672, which is in concordance with previous reports of IBAT 
inhibition in healthy volunteers22 and in patients with T2DM.27 Increased bile acid load in the 
colon increases colonic motility and reduces colonic transit time causing diarrhoea.32–34 In our 
study, severity of diarrhoea was mild to moderate and no patients discontinued GSK2330672 
or had their dose decreased. Taken together, the safety and tolerability profile of GSK2330672 
in patients seen in our study does not preclude further clinical investigation of the drug to treat 
patients with primary biliary cholangitis; however, gastrointestinal disturbance might 
ultimately limit the usefulness of this agent in practice. 
The key finding of this study is that GSK2330672 was significantly more efficacious than 
placebo in improving itch intensity. This was substantiated by decreases in pruritus scores 
measured by three different tools of itch measurement. GSK2330672 treatment was associated 
with improvement in pruritus and the changes from baseline were significant regardless of the 
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dosing sequence. Notably, pruritus scores improved within the first week of GSK2330672, 
continued to decrease through 2 weeks of treatment, and returned towards baseline on switch 
to blinded placebo. The improvement in pruritus severity seen in the placebo phases was in 
keeping with other trials of anti-pruritic agents in primary biliary cholangitis and was 
significantly exceeded by that seen in the active drug phases. 
Despite the differences in the results between intervention and placebo treatment, the 
magnitudes of the effect could be underestimated because the crossover study design lacked a 
washout between treatment periods. Incorporation of the analytical washout mitigates this 
somewhat, but placebo responses and carry-over effects still resulted in a sequence effect that 
influenced the magnitude of response depending on the order of treatment. Comparing the 
GSK2330672 period with the run-in open placebo period avoids the sequence effect and gives 
an alternative estimate of the magnitude of effect, although this might be an overestimation due 
to the unblinded placebo run-in being used to form this comparison. Nevertheless, individual 
patient responses (appendix) clearly showed rapid improvement of pruritus during 
GSK2330672 treatment and greater response was observed in patients with higher baseline itch 
intensity than in those with lower itch intensity. GSK2330672 also decreased sleep interference 
score, disability (5-D itch scale), and fatigue (PBC-40 scale) domain scores agreeing that the 
treatment had clinically meaningful effect on the symptom complex associated with primary 
biliary cholangitis. The study provides early evidence of effect in this debilitating symptomatic 
condition, but treatment duration was not sufficient to assess durability of benefit. This study 
had few patients and was not designed to deliver definitive conclusions on superiority of study 
drug over placebo. The interim analyses might have introduced some statistical bias in the 
estimated effect sizes, though as the interim analyses primarily assessed lack of effect we do 
not anticipate that this bias would greatly affect the results. Therefore, the efficacy of 
GSK2330672 on pruritus needs to be substantiated in larger studies of longer duration. 
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The evidence for the role of bile acids in the development of pruritus in primary biliary 
cholangitis has been equivocal, and the topic has been controversial.35 A strong association 
between plasma bile acid concentration and the severity of itch has never been recorded in 
cholestatic patients35 but other evidence has linked bile acid-mediated cholestatic pruritus via 
TGR5 receptors.36, 37 In this study, GSK2330672 treatment had substantial effect on the 
circulating bile acid pool, as shown by 50% decrease in serum total bile acid and decreased 
serum concentration of all taurine and glycine conjugated primary bile acids. These findings 
are consistent with a preferential effect of GSK2330672 on ileal reuptake of conjugated bile 
acids. However, we cannot exclude the possibility that pruritogens other than bile acids are 
also transported via IBAT. Cholesterol 7α-hydroxylase (CYP7A1), the rate limiting enzyme 
in hepatic bile acid synthesis, is regulated by farnesoid X receptor (FXR) and FGF19. 
Following GSK2330672 treatment we observed a significant 3-times increase in serum C4, a 
surrogate marker for hepatic CYP7A1 enzymatic activity.38 Fasting C4 has been shown to 
provide a good measure of the overall flux through the bile acid synthetic pathway and a 
reliable assessment of the degree of IBAT inhibition.27 Taken together, these findings suggest 
substantial target (i.e., IBAT) engagement and inhibition by GSK2330672. However, post-hoc 
correlation analyses estimated correlation coefficients between circulating biomarkers and 
pruritus scores to be less than 0・4, indicating that these markers are not highly associated with 
efficacy at an individual patient level after a short period of treatment. 
Lopixibat chloride (maralixibat or LUM001), an IBAT inhibitor, has been studied in a phase 2 
RCT as  a novel treatment of pruritus in patients with primary biliary cholangitis (CLARITY 
study).25 Although  the itch scores decreased from baseline in both lopixibat and placebo 
groups, lopixibat was not shown to be more efficacious than placebo in reducing pruritus. The 
negative result is likely to be, in part, due to a lower bile acid depleting effect of lopixibat. In 
our study, the effects of GSK2330672 on both total bile acid and C4 were more marked than 
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those reported with lopixibat; a finding which might explain the difference in clinical efficacy 
of the two agents.  
The significant decrease in serum FGF19 concentration observed in our study is consistent with 
decreased ileal FXR activation following IBAT inhibition. Decreased circulating 
concentrations of FGF19 result in decreased inhibition of hepatic bile acid synthesis, as 
reflected by increased serum C4 concentration. In this regard, the effect of GSK2330672 on 
FGF19 is different to that of other agents proposed for primary biliary cholangitis treatment. 
Obeticholic acid is a strong ileal FXR activator that increases FGF19 concentration and reduces 
bile acid synthesis, and fibrates reduce bile acid synthesis despite reduction in FGF19. The 
long-term use of an IBAT inhibitor is likely to maintain suppressed FGF19 and therefore, the 
effect of resulting upregulated bile acid synthesis on cholestasis needs careful investigation. 
However, the circulating bile acid pool is unlikely to expand as the loss of bile acids in faeces 
might exceed increased bile acid synthesis. The apparent paradox of contrasting actions of 
different agents in primary biliary cholangitis on FGF19 reflects that this is only an 
intermediate step in one pathway reducing bile acid concentration. If reduction in bile acid is 
the crucial pathway, then direct reduction through IBAT inhibition could be as valuable a 
mechanism as suppression of synthesis despite contrasting actions on FGF19. 
Autotaxin (ATX) has been proposed as a key potential factor in the pruritogenic pathway in 
cholestasis.39, 40 We observed significantly reduced serum ATX activity after treatment with 
GSK2330672 but not after placebo. It is possible that IBAT inhibition with GSK2330672 also 
interrupts the ileal reabsorption of an as yet unidentified molecule that might upregulate ATX 
activity, 41 which in turn decreases the expression or synthesis of ATX and reduces serum ATX 
concentration. Further work is required to probe the mechanisms involved in ATX effects of 
IBAT inhibitors. 
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The ability of GSK2330672 to remain in the gastrointestinal tract reduces concerns of systemic 
toxicity and drug interactions. Notably, GSK2330672 did not have any significant interaction 
with UDCA absorption or recycling. UDCA is not transported via IBAT and there was a 
significant increase in serum UDCA concentration after GSK2330672 treatment. However, the 
glyco (GUDCA) and tauro (TUDCA) conjugates of UDCA are transported by IBAT and we 
observed a 3–4-times decrease in their serum concentration. The clinical relevance of this effect 
is not known. Reassuringly, we did not observe any adverse effect of GSK2330672 on the 
therapeutic efficacy of UDCA since the serum liver biochemistry (mainly alkaline 
phosphatase) did not adversely increase during the study treatment. As UDCA is the mainstay 
of treatment in primary biliary cholangitis the clinical implication of inhibitory effect of 
GSK2330672 on UDCA conjugates merits further investigation. 
Overall, there were no significant changes in the liver enzymes following GSK2330672 
treatment. The absence of significance might be due to the short duration of treatment used in 
this study. Longer treatment with GSK2330672 could be required to study the effect of IBAT 
inhibition on alkaline phosphatase (biochemical marker of cholestasis) and other liver 
enzymes. 
This study was designed to efficiently gather information about potential effects of 
GSK2330672, which if sufficiently encouraging could be used to subsequently design a 
definitive trial. In this context, our study has several strengths. Firstly, this is the first crossover 
RCT of an IBAT inhibitor drug to treat pruritus in patients with primary biliary cholangitis. 
The crossover design of the study allowed estimation of the treatment effect in a few patients 
and provided a more efficient comparison of treatments than a similar sized parallel group trial. 
Secondly, we used patient reported outcomes to measure the treatment response objectively by 
using the existing validated tools (PBC-40 questionnaire and 5-D itch scale) and a novel, easy-
to-use electronic symptom diary. The study was not designed to make definitive conclusions 
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on superiority of the study drug over placebo treatment and it is limited by the small sample 
size, short duration (2 weeks) of treatment, and the absence of a washout period, as discussed 
above. Therefore the efficacy of GSK2330672 on pruritus needs to be substantiated by larger 
studies of longer duration.  
In conclusion, this phase 2a randomised controlled trial showed that 2 weeks of treatment with 
an oral  IBAT inhibitor GSK2330672 in patients with primary biliary cholangitis and symptoms 
of pruritus was safe, well tolerated, and was more efficacious than placebo in reducing the 
severity of pruritus. There was a significant reduction in serum total and conjugated bile acids, 
consistent with the postulated mechanism of efficacy, interruption of enterohepatic circulation 
of biliary pruritogens. Our results suggest that GSK2330672 could be a substantial advance for 
the treatment of pruritus in primary biliary cholangitis. Depending on its occurrence, duration, 
and effect in further studies, diarrhoea, the most common adverse event associated with 
GSK2330672, might limit the long-term use of this drug.  
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Figure 2 
Trial Profile 
  
28 
 
Table 1 
Baseline characteristics of volunteers 
  
29 
 
Table 2 
Summary of adverse events 
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Figure 3 
Changes from baseline in itch intensity scores according to treatment period (A) 0–10 
numerical rating scale. (B) Primary biliary cholangitis-40 itch domain score. (C) 5-D itch scale.  
Error bars are 95% CI. LS=least squares. 
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Figure 4 
Changes in serum total bile acids and C4 according to treatment period. Following treatment 
with GSK2330672 a significant decrease in total bile acid (A) and significant increase in C4 
(B) was seen. Data shown are geometric mean values and error bars show 95% CI. 
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